Sartorius Stedim Biotech: dynamic start to the year

(CercleFinance.com) - Sartorius Stedim Biotech shares are up over 4% in Paris on Thursday, as investors hailed the good start to the fiscal year recorded by the supplier of equipment and services for the biopharmaceutical industry.


This included double-digit growth - in both revenue and profit.

Q1 revenues increased by 27.6% y-o-y and at constant exchange rates, reaching 862 million euros.

Meanwhile, Ebitda jumped 31.1% to 304 million euros, giving a margin that was pretty much stable at 35.2%, compared with 35.4% a year earlier.

In light of this Q1 performance, the biopharmaceutical industry partner confirmed its outlook for FY 2022, still targeting sales growth of 15% to 19%, with an Ebitda margin of over 35%.

At around 2.30 pm, the share was up about 4%, over double the Paris market.


Copyright (c) 2022 CercleFinance.com. All rights reserved.